SEPTInvestingStart Free

GSK 6-K: Fda approval

GSK

Filed with the SEC on · accession 0001654954-26-009743

GSK filed a 6-K (foreign company report) with the SEC on Nov 13, 2026. GSK announced that the EMA's CHMP issued a positive opinion recommending a label update for Bexsero (4CMenB) to include a single booster dose for individuals aged 10 years and older previously vaccinated at least two years earlier.

Summary of the filing

GSK announced that the EMA's CHMP issued a positive opinion recommending a label update for Bexsero (4CMenB) to include a single booster dose for individuals aged 10 years and older previously vaccinated at least two years earlier. The recommendation follows positive Phase IIIb data showing immune memory from infant vaccination can be boosted up to 19 years later.

For details, click here →How to read a 6-K →

Key details

Issuer/manufacturer of bexseroGSK plc
Regulatory body issuing positive opinionEuropean Medicines Agency (EMA) / CHMP
Senior vice president, r&d vaccines & infectious diseases, gskSanjay Gurunathan

✦ Ask GOAX AI about this filing — what it means for GSK, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for GSK?

Click here

Frequently asked questions

What did GSK file with the SEC on Nov 13, 2026?

GSK filed a 6-K (Fda approval). GSK announced that the EMA's CHMP issued a positive opinion recommending a label update for Bexsero (4CMenB) to include a single booster dose for individuals aged 10 years and older previously vaccinated at least two years earlier. The recommendation follows positive Phase IIIb data showing immune memory from infant vaccination can be boosted up to 19 years later.

What does a fda approval mean for GSK stock?

For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.

How do I read a 6-K?

How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.

Other GSK SEC filings

Get alerts when GSK files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
GSK overviewGSK analysisGSK newsLatest SEC filings